表紙
市場調查報告書

類天疱瘡:開發中產品分析

Bullous Pemphigoid - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410984
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
類天疱瘡:開發中產品分析 Bullous Pemphigoid - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 120 Pages
簡介

類天疱瘡是一種慢性,炎性,表皮下起泡性的疾病。如果不進行治療,它可以經年累月一直反覆持續著自然緩和及加重的時期。該疾病可能致命,特別是對較為虛弱的患者。

本報告提供類天疱瘡的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類天疱瘡 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

開發治療藥的企業

  • iCo Therapeutics Inc.
  • Immungenetics AG
  • True North Therapeutics Inc
  • TxCell SA

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11811IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Pipeline Review, H2 2019, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 6, 2 and 4 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bullous Pemphigoid - Overview
    • Bullous Pemphigoid - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Bullous Pemphigoid - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bullous Pemphigoid - Companies Involved in Therapeutics Development
    • Akari Therapeutics Plc
    • Alkahest Inc
    • Amgen Inc
    • Eli Lilly and Co
    • Genzyme Corp
    • iCo Therapeutics Inc
    • Immungenetics AG
    • Regeneron Pharmaceuticals Inc
    • Sangamo Therapeutics Inc
    • viDA Therapeutics Inc
  • Bullous Pemphigoid - Drug Profiles
  • Bullous Pemphigoid - Dormant Projects
  • Bullous Pemphigoid - Discontinued Products
  • Bullous Pemphigoid - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bullous Pemphigoid, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Bullous Pemphigoid - Pipeline by Akari Therapeutics Plc, H2 2019
  • Bullous Pemphigoid - Pipeline by Alkahest Inc, H2 2019
  • Bullous Pemphigoid - Pipeline by Amgen Inc, H2 2019
  • Bullous Pemphigoid - Pipeline by Eli Lilly and Co, H2 2019
  • Bullous Pemphigoid - Pipeline by Genzyme Corp, H2 2019
  • Bullous Pemphigoid - Pipeline by iCo Therapeutics Inc, H2 2019
  • Bullous Pemphigoid - Pipeline by Immungenetics AG, H2 2019
  • Bullous Pemphigoid - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Bullous Pemphigoid - Pipeline by Sangamo Therapeutics Inc, H2 2019
  • Bullous Pemphigoid - Pipeline by viDA Therapeutics Inc, H2 2019
  • Bullous Pemphigoid - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Bullous Pemphigoid, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top